Saracatinib (AZD0530)

Catalog No.S1006

Saracatinib (AZD0530) is a potent Src inhibitor with IC50 of 2.7 nM in cell-free assays, and potent to c-Yes, Fyn, Lyn, Blk, Fgr and Lck; less active for Abl and EGFR (L858R and L861Q). Phase 2/3.

Price Stock Quantity  
USD 91 In stock
USD 70 In stock
USD 170 In stock
USD 670 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Saracatinib (AZD0530) Chemical Structure

Saracatinib (AZD0530) Chemical Structure
Molecular Weight: 542.03

Validation & Quality Control

Cited by 35 publications:

8 customer reviews :

Quality Control & MSDS

Related Compound Libraries

Src Inhibitors with Unique Features

  • Most Potent Src Inhibitor

    Dasatinib Src, IC50=0.8 nM.

  • FDA-approved Src Inhibitor

    Bosutinib (SKI-606) Approved by FDA for Ph+ chronic myelogenous leukemia (CML).

  • Newest Src Inhibitor

    PP1 Potent and selective Src inhibitor for Lck/Fyn with IC50 of 5 nM/ 6 nM.

  • Classic Src Inhibitor

    KX2-391 The first clinical Src inhibitor (peptidomimetic class) that targets the peptide substrate site of Src, with GI50 of 9-60 nM in cancer cell lines.

Product Information

  • Compare Src Inhibitors
    Compare Src Products
  • Research Area
  • Inhibition Profile
  • Saracatinib (AZD0530) Mechanism
  • Combination Therapy
    Combination Therapy

Product Description

Biological Activity

Description Saracatinib (AZD0530) is a potent Src inhibitor with IC50 of 2.7 nM in cell-free assays, and potent to c-Yes, Fyn, Lyn, Blk, Fgr and Lck; less active for Abl and EGFR (L858R and L861Q). Phase 2/3.
Targets c-Src [2]
(Cell-free assay)
LCK [2]
(Cell-free assay)
c-YES [2]
(Cell-free assay)
EGFR (L861Q) [2]
(Cell-free assay)

 View  More

IC50 2.7 nM <4 nM 4 nM 4 nM
In vitro Saracatinib also potently inhibits other Src tyrosine kinase family members including c-Yes, Fyn, Lyn, Blk, Fgr, and Lck with IC50 from 4-10 nM. Saracatinib sensitively inhibits Src Y530F NIH 3T3 with IC50 of 80 nM. Saracatinib significantly impairs the invasion of HT1080 cells through a 3-dimensional collagen matrix and completely inhibits EGF-induced cell scattering in NBT-II bladder cancer cells. [1] Saracatinib potent inhibits Src activation in DU145 and PC3 cells, which through inhibition of Y419 phosphorylation. Saracatinib inhibits the growth of prostate cancer including PC3, DU145, CWR22Rv1 and LNCaP, while Saracatinib shows low activity in LAPC-4, PZ-HPV7 and RWPE-1 cells. Saracatinib induces cell cycle arrest at G1/S but not caspase 3 cleavages. Saracatinib also significantly inhibits DU145 and PC3 migration in the Boyden chamber. [2] Saracatinib gives a potent and sustained blockage of AKT and enhances the sensitivity to irradiation in A549 and Calu-6 cells. [3] Saracatinib inhibits osteoclast in activity, resorption and formation. Saracatinib also reversibly prevents osteoclast precursor migration. [4]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
CTV-1MmS5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVH5WJd7UUN3ME2wMlA3OTR|IN88US=>Ml[zV2FPT0WU
LAMA-84NXfmdpFjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUXJR|UxRTBwMUW5PUDPxE1?NHuxbI5USU6JRWK=
MEG-01NF25NFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NF2wb|dKSzVyPUCuNlM3QDhizszNMXfTRW5ITVJ?
EM-2M{Tw[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NI\GVppKSzVyPUCuNlY2KM7:TR?=NI\nNIVUSU6JRWK=
TE-15NX7PUYJ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFPqUYdKSzVyPUCuNlc1OTJizszNNVqwXlB7W0GQR1XS
NCI-H1648NV7hOZBwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVfs[IlTUUN3ME2wMlI5OTF4IN88US=>MYLTRW5ITVJ?
TE-12MlPMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4nvPGlEPTB;MD6zNlY5KM7:TR?=NUTtUmVJW0GQR1XS
LB996-RCCM{m2[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M37IRWlEPTB;MD60OFE6PiEQvF2=NGj3e2lUSU6JRWK=
K-562M1nITGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVHJR|UxRTBwNES5Olch|ryPM3K1NXNCVkeHUh?=
D-336MGNIfY[ZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Moe1TWM2OD1yLkWwN|A1KM7:TR?=MYnTRW5ITVJ?
NOS-1NXz6fpRlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF\rTFRKSzVyPUCuOlA2OjlizszNM1LSfnNCVkeHUh?=
EW-24MmnDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXfJR|UxRTBwNkK2PVMh|ryPNXHvXGJ3W0GQR1XS
BV-173M{jrV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3\iXmlEPTB;MD62OVI1QSEQvF2=M3GycXNCVkeHUh?=
NCCITNGf4OYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MX7JR|UxRTBwN{OyNVgh|ryPMXHTRW5ITVJ?
NCI-H1436NHPjUYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MorSTWM2OD1yLke5NFQ6KM7:TR?=NF3HcYpUSU6JRWK=
BB30-HNCMX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NV7uOWRmUUN3ME2wMlg3OjB|IN88US=>NXrkTIxUW0GQR1XS
TE-8NFXxemFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1fTdWlEPTB;MD64O|I4PSEQvF2=MnfiV2FPT0WU
A704MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVLtUJFOUUN3ME2wMlg6OjFizszNNX\6SVVPW0GQR1XS
TK10MmnaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlT6TWM2OD1yLkmwOlY6KM7:TR?=MVfTRW5ITVJ?
KS-1MkToS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFPKR|NKSzVyPUGuNVk4PzlizszNNYTuN4J6W0GQR1XS
C2BBe1MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYrpSotJUUN3ME2xMlIxPTB5IN88US=>M{fWNnNCVkeHUh?=
RXF393NYHuTYVJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGHMZ5ZKSzVyPUGuNlQ{PiEQvF2=NEfFVW5USU6JRWK=
KGNNYrLPYwxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MW\JR|UxRTFwMke2PFch|ryPNWfJO|cxW0GQR1XS
NB69M1T0N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYDJR|UxRTFwM{e0PVch|ryPMnzjV2FPT0WU
TE-11MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUPJR|UxRTFwNEO0NVgh|ryPMUHTRW5ITVJ?
TE-1MmXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmXTTWM2OD1zLkS0NVA2KM7:TR?=MlXUV2FPT0WU
ST486NEPnOHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{f6bWlEPTB;MT60OVg2OiEQvF2=Mo\RV2FPT0WU
HOP-62NGG1W|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWTYRnVlUUN3ME2xMlUxOjR4IN88US=>M37KR3NCVkeHUh?=
EW-16MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoO4TWM2OD1zLkW1NFg{KM7:TR?=NWjI[4lrW0GQR1XS
LB1047-RCCMVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M33tS2lEPTB;MT61OVQ2OyEQvF2=M{jpb3NCVkeHUh?=
TE-10MnnxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVLzPI9YUUN3ME2xMlY3OjV{IN88US=>MX;TRW5ITVJ?
RL95-2MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUnJR|UxRTFwNk[5NFIh|ryPMYLTRW5ITVJ?
DOHH-2MkTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2OybGlEPTB;MT63NVc5OiEQvF2=NYHWbVd4W0GQR1XS
MFH-inoMWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUjBbG1KUUN3ME2xMlc4QDdizszNMn7DV2FPT0WU
GB-1MoqyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkjFTWM2OD1zLke5PFM{KM7:TR?=MYHTRW5ITVJ?
SK-N-DZMmTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF30OoVKSzVyPUGuPFQ3QDhizszNNFvmWWFUSU6JRWK=
OS-RC-2MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUfmfGR5UUN3ME2xMlg5PTd2IN88US=>NWHMemRuW0GQR1XS
SW982MknlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mo\qTWM2OD1zLkmyNFk{KM7:TR?=NW\xTHJUW0GQR1XS
KALS-1M1fBbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlnvTWM2OD1zLkm4O|IzKM7:TR?=MkDkV2FPT0WU
TGBC24TKBNVi4bHRHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFGzboFKSzVyPUKuNFU6PThizszNNX7yb4ttW0GQR1XS
GI-1MkfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXjJR|UxRTJwMU[wPFQh|ryPMUHTRW5ITVJ?
SW962MkPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Moe2TWM2OD1{LkG3NVc5KM7:TR?=M3fGV3NCVkeHUh?=
SW872NEDRVYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXziWGcxUUN3ME2yMlE5PTB5IN88US=>NEPTfnhUSU6JRWK=
NCI-H747MmHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4nVUmlEPTB;Mj6yOVcyPCEQvF2=MnjZV2FPT0WU
MZ1-PCMY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkXFTWM2OD1{LkK5N|U3KM7:TR?=MVjTRW5ITVJ?
MSTO-211HMV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M37a[mlEPTB;Mj6zOVczOyEQvF2=MV7TRW5ITVJ?
BL-70M3T2Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmrHTWM2OD1{LkS3OFIzKM7:TR?=M1fEOHNCVkeHUh?=
SW954Mle5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYHkNGdpUUN3ME2yMlU4PDB6IN88US=>M1KxfXNCVkeHUh?=
SNB75NIG2NIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXTJR|UxRTJwNki1PVQh|ryPNWKyV2FkW0GQR1XS
IST-SL2MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUPJR|UxRTJwN{KzO|kh|ryPM4XONnNCVkeHUh?=
GCIYNXHMW29HT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF;0[WhKSzVyPUKuPFcxODVizszNM{\rcHNCVkeHUh?=
KU812NVLndGdpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3XuVWlEPTB;Mz6wOVI6QSEQvF2=M2\MeHNCVkeHUh?=
LXF-289MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1XncWlEPTB;Mz6xNlExQSEQvF2=MlTRV2FPT0WU
ETK-1NXXGUYRDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mk\uTWM2OD1|LkKwO|Y4KM7:TR?=NHT2S4xUSU6JRWK=
SF126MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV3JR|UxRTNwM{GxO|Qh|ryPNID0dmFUSU6JRWK=
LC-2-adM3vjRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NF6zT4VKSzVyPUOuOVU4KM7:TR?=M3nQeXNCVkeHUh?=
KNS-42M{TnVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYPJR|UxRTNwNkWg{txOM1rQSHNCVkeHUh?=
OVCAR-4NYGzOZpQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXjLeYxCUUN3ME2zMlc{PDN|IN88US=>MWLTRW5ITVJ?
PF-382NVjJV2EyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGKyN|RKSzVyPUOuPFM3QThizszNNIPCb4pUSU6JRWK=
SH-4M3OyVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXHUenV7UUN3ME20MlI2OjV7IN88US=>MY\TRW5ITVJ?
KM12NXfKTXFnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX\JR|UxRTRwM{K0NVYh|ryPMnrnV2FPT0WU
NB5MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWrqdXZXUUN3ME20MlQyQDZ2IN88US=>NXXaT4ZkW0GQR1XS
KURAMOCHIMYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NV;jTJRjUUN3ME20MlY2OjV4IN88US=>M1LMenNCVkeHUh?=
BeckerMmrhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MULJR|UxRTRwNk[0NVYh|ryPMVfTRW5ITVJ?
MV-4-11NEfFSHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEDUbpVKSzVyPUSuPFE{PDRizszNMn\lV2FPT0WU
KINGS-1M{H0bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3jz[2lEPTB;ND64NlM4OyEQvF2=NIDJWndUSU6JRWK=
LS-123M33Dc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1XIeWlEPTB;NT60PVY5PCEQvF2=MlrDV2FPT0WU
SF268NWT6ZVFkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoDwTWM2OD13Lk[xNlYzKM7:TR?=M{L3fnNCVkeHUh?=
A388NE\mfoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVzJR|UxRTVwNkO2Olch|ryPNILHSJZUSU6JRWK=
NMC-G1NF3xRnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoH1TWM2OD14LkCxPFEyKM7:TR?=MWfTRW5ITVJ?
CGTH-W-1M4DRb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mk\tTWM2OD14LkCyNFc2KM7:TR?=NEXZdo1USU6JRWK=
ES4MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4TYRmlEPTB;Nj61N|A4PCEQvF2=MWDTRW5ITVJ?
SRNUf4bmFlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGK2b|FKSzVyPU[uOVg5ODdizszNM2rjd3NCVkeHUh?=
BB49-HNCNU\uZm5mT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MorhTWM2OD14LkezNlA3KM7:TR?=MorLV2FPT0WU
KLEMY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVvhWIVRUUN3ME22Mlc5Ozd5IN88US=>MmXTV2FPT0WU
HUTU-80Ml\iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVXYNG0xUUN3ME22Mlk5PDZ4IN88US=>NIL1W3NUSU6JRWK=
SNU-C2BM4jUdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnnqTWM2OD15LkiyO|M4KM7:TR?=M{jGcHNCVkeHUh?=
BB65-RCCNHXBNVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX7EWYVyUUN3ME23Mlk1QTB2IN88US=>NYj4TohKW0GQR1XS
QIMR-WILNVjxWXZ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXvDR4RMUUN3ME24MlQzQDB6IN88US=>Mme4V2FPT0WU
GDM-1MmXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M33KOWlEPTB;OD65O|I6OiEQvF2=M{XuS3NCVkeHUh?=
LC4-1NEL0Ro5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{P5fWlEPTB;OT6wNFkyOSEQvF2=MXPTRW5ITVJ?
MLMAMXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2TLTGlEPTB;OT6xOVAxPiEQvF2=M4XHS3NCVkeHUh?=
EoL-1-cellMoqwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVvsWoxiUUN3ME25MlMxOTl{IN88US=>M33WOXNCVkeHUh?=
BOKUMVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{XKUGlEPTB;OT65OlQ3PiEQvF2=NYHNO2t4W0GQR1XS
EVSA-TNVq2TY9ET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYPhemNYUUN3ME2xNE43PTZ6IN88US=>NWDUcXpoW0GQR1XS
D-283MEDNUnIUldQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFvid2hKSzVyPUGwMlkyPzZizszNMmXVV2FPT0WU
NB1MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4HuZWlEPTB;MUGuNFI1OiEQvF2=MlLXV2FPT0WU
RPMI-8402M3nZSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnL6TWM2OD1zMT6xO|gh|ryPNWPWfY1VW0GQR1XS
NCI-H1355MmLvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGDXTWZKSzVyPUGxMlE5ODZizszNNInCTFZUSU6JRWK=
NB7NVHm[2dST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWfUO2xZUUN3ME2xNU4{Ojl5IN88US=>NF;WSZhUSU6JRWK=
RPMI-6666NXr3S5lTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmHtTWM2OD1zMj65OVY4KM7:TR?=M2fxfHNCVkeHUh?=
697M3zveWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXPJR|UxRTF|LkK3NFEh|ryPNUmyc3hbW0GQR1XS
CTB-1NWHRclhpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2LRVWlEPTB;MUOuOVk1QCEQvF2=MkLKV2FPT0WU
VA-ES-BJNYW5VZpwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF\XZppKSzVyPUGzMlkzOzRizszNMYPTRW5ITVJ?
BE-13M4PKPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVXJR|UxRTF2LkO5NVUh|ryPM2\HbnNCVkeHUh?=
SKM-1NYfHd2lqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGLGdWVKSzVyPUG0MlQ1QTlizszNMni0V2FPT0WU
TE-6NE\ENIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUTJR|UxRTF2Lke1PVEh|ryPNF3ENIZUSU6JRWK=
LB771-HNCMmXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NETOdXNKSzVyPUG0Mlc5QThizszNM4XmRnNCVkeHUh?=
ECC4NHHOZplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnzoTWM2OD1zNz6wNlc4KM7:TR?=MUjTRW5ITVJ?
ES3NEfnVmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoHITWM2OD1zNz60OlU2KM7:TR?=M1u0O3NCVkeHUh?=
LB647-SCLCM3H1XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVu0W5djUUN3ME2xO{41QTR7IN88US=>Ml6yV2FPT0WU
NB10NYDTd3dbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX;4ZY5RUUN3ME2xPE42OjV4IN88US=>MWPTRW5ITVJ?
L-540MoP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWPJR|UxRTF6LkixNFkh|ryPNU\zeY5DW0GQR1XS
NCI-H2126MkXtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF72empKSzVyPUG5MlUyKM7:TR?=MoP2V2FPT0WU
HHM4W2c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIDYUYFKSzVyPUKwMlAxQTlizszNMkSyV2FPT0WU
MPP-89M4m1OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV7JR|UxRTJ|LkKyPFkh|ryPMYLTRW5ITVJ?
IST-MEL1M{G4UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4XJ[2lEPTB;MkOuPFY2QCEQvF2=M4q4PXNCVkeHUh?=
KP-N-YSNFP2PYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGroOolKSzVyPUKzMlkzPTVizszNMonmV2FPT0WU
EC-GI-10MmrUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIfVeFhKSzVyPUK0MlU6QDlizszNNIDO[YJUSU6JRWK=
EKVXNYD2eIdlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHLOTnZKSzVyPUK2MlAzODNizszNMmTIV2FPT0WU
TGBC1TKBNFT2N2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVX3fm1ZUUN3ME2yOk41OzRizszNMmHYV2FPT0WU
DaudiNHG1RWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHnZelRKSzVyPUK3MlA4PzNizszNNVXYNHdKW0GQR1XS
ALL-POMUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVnJR|UxRTJ5LkC4NUDPxE1?NUXmd4ViW0GQR1XS
NB6NF3wVVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFTyV2ZKSzVyPUK3MlQ5QCEQvF2=NUnoc|l{W0GQR1XS
ES6NHnFXY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkPPTWM2OD1{Nz65NVI{KM7:TR?=M13iSnNCVkeHUh?=
COLO-320-HSRNF:2OndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHPWXYRKSzVyPUK4MlA{PzNizszNM{nPbHNCVkeHUh?=
K5MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYDJR|UxRTJ6LkGyPFch|ryPMlXRV2FPT0WU
ES1MmfiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYfOUlhiUUN3ME2yPE44Pzd|IN88US=>MmThV2FPT0WU
LC-1FNFS2SWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M33UTWlEPTB;MkmuO|M1PiEQvF2=NV3pOZpxW0GQR1XS
SCLC-21HMmX1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkDBTWM2OD1|MD63N|E4KM7:TR?=M1HuOHNCVkeHUh?=
SK-PN-DWMUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVPiNZg1UUN3ME2zNk42PTl6IN88US=>MWHTRW5ITVJ?
D-247MGMnH2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVW2[GpqUUN3ME2zNk46Pzd|IN88US=>Mn;kV2FPT0WU
TE-5NUDkNZl1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYLJR|UxRTN|LkCzOlIh|ryPNUHtRVllW0GQR1XS
MONO-MAC-6M3uxOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGTuemtKSzVyPUOzMlUxPDhizszNMnjpV2FPT0WU
LB2518-MELMVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2L2bGlEPTB;M{OuO|Y3PiEQvF2=M17kU3NCVkeHUh?=
LOXIMVINELjXopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXi4[W9sUUN3ME2zN{44QTJ6IN88US=>Mm\XV2FPT0WU
NCI-H209Mmi3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{fDUmlEPTB;M{WuNVQ1KM7:TR?=M3LnR3NCVkeHUh?=
A253MnLWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYTJR|UxRTN3Lke0Nlkh|ryPMYfTRW5ITVJ?
HCC1599NHHkcW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M32zOGlEPTB;M{[uO|A2OyEQvF2=MUnTRW5ITVJ?
EB-3MmXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmTsTWM2OD1|Nj65OVE5KM7:TR?=NWrzXYlUW0GQR1XS
GOTOMlj6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYrJR|UxRTN5LkOyNlQh|ryPNEPLNHVUSU6JRWK=
SW684NUHMU2NRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlPrTWM2OD12MT64OFk2KM7:TR?=NIjkNGZUSU6JRWK=
DELMUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4DDXGlEPTB;NEKuNFUzOiEQvF2=NGnXfZFUSU6JRWK=
HT-144NF\jeFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWLJR|UxRTR{LkG2O|Yh|ryPNGXCPJRUSU6JRWK=
TE-9MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2TJb2lEPTB;NEOuOFU6PiEQvF2=Mnq3V2FPT0WU
KARPAS-45M4X0Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIHmR4hKSzVyPUS0MlM6OjVizszNNYnYe3Q1W0GQR1XS
HAL-01M3rv[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGC5T|BKSzVyPUS0MlUxOzRizszNMWPTRW5ITVJ?
RCC10RGBNV7yTY9ET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVfJR|UxRTR2LkezPVIh|ryPMUfTRW5ITVJ?
CP67-MELMmjvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3TUSGlEPTB;NEWuOlI1OSEQvF2=MmH5V2FPT0WU
NB17MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUTJR|UxRTR3Lk[2OFMh|ryPM{fpUHNCVkeHUh?=
SK-UT-1M3HNWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV3rV4dCUUN3ME20OU46PDZ2IN88US=>M4LnfnNCVkeHUh?=
JiyoyeP-2003MoDnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlLGTWM2OD12Nj6wNVE6KM7:TR?=MXnTRW5ITVJ?
HCE-4M{Hib2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NF\xfJpKSzVyPUS2MlU6PjhizszNNIfMRVNUSU6JRWK=
NCI-H720MkfES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWjwSXhCUUN3ME20Ok44Pjh{IN88US=>NYXHeXUzW0GQR1XS
KARPAS-422NXTFRVVqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWfJR|UxRTR5LkC4PVUh|ryPNWnqcpVnW0GQR1XS
Ramos-2G6-4C10M{mwb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnPYTWM2OD12Nz6xOlIzKM7:TR?=NFn3fpZUSU6JRWK=
HCE-TNFHjNFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NILUWlRKSzVyPUS3MlY5OjhizszNNGTEeolUSU6JRWK=
PSN1NH7BfpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M36ycGlEPTB;NEeuO|gyOyEQvF2=NH\PS25USU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo Saracatinib shows great tumor growth inhibition in Src3T3 allografts and a moderate growth delay in Calu-6, MDA-MB-231, AsPc-1 and BT474C xenografts. [1] Saracatinib shows great antitumor activity in orthotopic DU145 xenograft mice at a dose of 25mg/kg (orally administered, daily). [2]
Features The 1st Src inhibitor to show inhibition of the Src pathway in human tumor tissue.

Protocol(Only for Reference)

Kinase Assay: [1]

Kinase Assay IC50 of tyrosine kinase activity is measured by an enzyme-linked immunosorbent assay (ELISA) with recombinant catalytic domains of a panel of receptor and non-receptor tyrosine kinases (in some cases only part of the catalytic domain is used). Saracatinib dose ranges from 0.001-10 mM. Specificity assays against a panel of serine/threonine kinases are performed using a filter capture assay with 32P. Briefly, multidrop 384 plates containing 0.5 μL Saracatinib or controls (DMSO) alone or pH 3.0 buffer controls) are incubated with 15 μL of enzyme plus peptide/protein substrate for 5 min before the reaction is initiated by the addition of 10 μL of 20 mM Mg-ATP. For all enzymes the final concentration is approximated to the Michaelis constant (Km). Assays are carried out for 30min at room temperature before termination by the addition of 5 μL orthophosphoric acid. After mixing, the well contents are harvested onto a P81 Unifilter plate, using orthophosphoric acid as the wash buffer. Then IC50 is calculated.

Cell Assay: [1]

Cell lines PC3, DU145, CWR22Rv1, LNCaP, LAPC-4, PZ-HPV7 and RWPE-1 cells
Concentrations 62.5 nM - 16 mM
Incubation Time 1, 3 and 5 days
Method Cells are seeded at a density of 2× 103 in 96-well plates and incubated overnight. Then Saracatinib (62.5 nM-16 mM) is added to the cells. After 1, 3 and 5 days, culture medium is removed followed by addition of 0.2 mL DMSO per well and continuous shaking of plates at 200 rotations per minute for 15min. Then IC50 is measured by MTT metho

Animal Study: [1]

Animal Models CB17 mice are implanted with DU145 cells.
Formulation Dissolved in 0.5% hydroxypropyl methylcellulose, 0.1% Tween 80
Dosages 25 mg/kg
Administration Orally administered daily

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Chang YM, Oncogene, 2008, 27(49), 6365-6375.

[2] Green TP, et al. Mol Oncol, 2009, 3(3), 248-261.

view more

Clinical Trial Information( data from http://clinicaltrials.gov, updated on 2016-07-30)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT02737202 Recruiting Pulmonary Lymphangioleiomyomatosis Baylor College of Medicine|University of Cincinnati|Brigh  ...more Baylor College of Medicine|University of Cincinnati|Brigham and Womens Hospital|Stanford University|Loyola University|University of South Florida|National Institutes of Health (NIH) April 2016 Phase 2
NCT02732587 Active, not recruiting Alcohol Drinking Yale University|National Institute on Alcohol Abuse and A  ...more Yale University|National Institute on Alcohol Abuse and Alcoholism (NIAAA) November 2015 Phase 1
NCT02167256 Recruiting Alzheimers Disease Yale University|Alzheimers Therapeutic Research Institute December 2014 Phase 2
NCT02262026 Recruiting Alcoholism Yale University November 2014 Phase 1
NCT02116712 Completed Pulmonary Lymphangioleiomyomatosis Tony Eissa|University of Texas|University of Cincinnati|B  ...more Tony Eissa|University of Texas|University of Cincinnati|Baylor College of Medicine August 2014 Phase 1

view more

Chemical Information

Download Saracatinib (AZD0530) SDF
Molecular Weight (MW) 542.03
Formula

C27H32ClN5O5

CAS No. 379231-04-6
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms N/A
Solubility (25°C) * In vitro DMSO 35 mg/mL warming (64.57 mM)
Ethanol 31 mg/mL (57.19 mM)
Water <1 mg/mL (<1 mM)
In vivo 2% DMSO+30% PEG 300+ddH2O 5mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name N-(5-chlorobenzo[d][1,3]dioxol-4-yl)-7-(2-(4-methylpiperazin-1-yl)ethoxy)-5-(tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine

Frequently Asked Questions

  • Question 1
    What is the half-life of Saracatinib?

    Answer: Based on the following paper, the half-life of Saracatinib in vivo is around 40hours and it reaches its peak lever around 2-4 hours after dosing: http://clincancerres.aacrjournals.org/content/16/19/4876.long

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related Src Products

  • Dasatinib Monohydrate

    Dasatinib Monohydrate is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM, respectively.

  • SU6656

    SU 6656 is a selective Src family kinase inhibitor with IC50 of 280 nM, 20 nM, 130 nM, and 170 nM for Src, Yes, Lyn, and Fyn, respectively.

  • PX-478 2HCl

    PX-478 2HCl is an orally active, and selective hypoxia-inducible factor-1α (HIF-1α) inhibitor. Phase 1.

  • Bosutinib (SKI-606)

    Bosutinib (SKI-606) is a novel, dual Src/Abl inhibitor with IC50 of 1.2 nM and 1 nM in cell-free assays, respectively.

  • Dasatinib

    Dasatinib is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively.

  • KX2-391

    KX2-391, the first clinical Src inhibitor (peptidomimetic class) that targets the peptide substrate site of Src, with GI50 of 9-60 nM in cancer cell lines. Phase 2.

  • PP1

    PP1 is a potent and selective Src inhibitor for Lck/Fyn with IC50 of 5 nM/ 6 nM.

  • PP2

    PP2, a Src family kinase inhibitor, potently inhibits Lck/Fyn with IC50 of 4 nM/5 nM in cell-free assays, ~100-fold less potent to EGFR, inactive for ZAP-70, JAK2 and PKA.

  • WH-4-023

    WH-4-023 is a potent and orally active Lck/Src inhibitor with IC50 of 2 nM and 6 nM in cell-free assays, respectively.

  • Ibrutinib (PCI-32765)

    Ibrutinib (PCI-32765) is a potent and highly selective Brutons tyrosine kinase (Btk) inhibitor with IC50 of 0.5 nM in cell-free assays, modestly potent to Bmx, CSK, FGR, BRK, HCK, less potent to EGFR, Yes, ErbB2, JAK3, etc.

Recently Viewed Items

Tags: buy Saracatinib (AZD0530) | Saracatinib (AZD0530) supplier | purchase Saracatinib (AZD0530) | Saracatinib (AZD0530) cost | Saracatinib (AZD0530) manufacturer | order Saracatinib (AZD0530) | Saracatinib (AZD0530) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us